2
0This collection of research excerpts explores the current landscape and future trajectory of antibody-drug conjugates (ADCs) in oncology. The sources highlight the critical evolution of precision medicine, emphasizing how next-generation therapies must address challenges like antigen heterogeneity and complex resistance mechanisms. By integrating multidimensional biomarkers and advanced imaging techniques, researchers aim to refine patient selection and improve the therapeutic window. The text also details the shift toward rational drug combinations and the development of bispecific ADCs to enhance efficacy while minimizing toxicities. Ultimately, these findings provide a comprehensive framework for advancing ADCs from late-stage salvage treatments to personalized early-intervention strategies.
References:
Pistilli B, Colombo R, Mosele M F, et al. Antibody-drug conjugates in precision oncology[J]. Cancer Cell, 2026, 44(6): 1126-1146.
